Navigation Links
Rate of chronic health problems for low-birth-weight children does not increase in adolescence
Date:7/27/2011

In a follow-up of extremely low-birth-weight children, the rates of chronic health conditions overall, and asthma specifically, did not change between the ages of 8 and 14 years, although the rate of obesity did increase, according to a study in the July 27 issue of JAMA.

Changes in perinatal care in the 1990s resulted in improved survival among extremely low-birth-weight (ELBW) infants (weight less than 2.2 lbs.).

"The school-aged outcomes for these children indicate very high rates of chronic health conditions and developmental problems compared with normal-birth-weight (NBW) controls. There have been few reports of the outcomes of ELBW children during adolescence, which is a time of enormous social, health, and developmental change," according to background information in the article.

Maureen Hack, M.B., Ch.B., of University Hospitals Rainbow Babies & Children's Hospital and Case Western Reserve University School of Medicine, and colleagues conducted a study to examine changes in the rates of chronic conditions of ELBW children between the ages of 8 and 14 years. In a previous study, the authors reported that compared with NBW controls, ELBW children at 8 years of age had significantly higher rates of chronic conditions, functional limitations, and special health care needs. The current study, conducted from 2004 through 2009, included 181 ELBW children from the previous study and 115 NBW controls of similar sociodemographic status, born from 1992 through 1995.

Within the ELBW group, the overall rates of chronic conditions did not change between the ages of 8 and 14 years (75 percent and 74 percent, respectively) but there was a significant decrease in the average number of chronic conditions per child. On measures of functional limitation, the rates decreased significantly from 56 percent to 46 percent. In a comparison of the groups, the significantly higher rates and numbers of chronic conditions among the ELBW c
'/>"/>

Contact: George Stamatis
george.stamatis@uhhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Vitamin E shows possible promise in easing chronic inflammation
2. New research lights up chronic bacterial infection inside bone
3. When acute hepatitis develops into chronic hepatitis
4. Research uncovers promising target to treat chronic abdominal pain
5. New trigger for chronic inflammation in rheumatoid arthritis discovered
6. Early-life experience linked to chronic diseases later in life: UBC research
7. NHLBI awards $11 million for molecular roadmap to chronic lung diseases
8. New potential to treat chronic obstructive pulmonary disease
9. Higher opioid dose linked to overdose risk in chronic pain patients
10. Discovery of new type of immune cells regulating inflammation in chronic diseases
11. New data on highly effective treatment for chronic rhinosinusitis with nasal polyps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
(Date:7/24/2014)... 3.5 billion years of evolutionary trial and error, is ... may be reaching a tipping point. , In a ... published in Science , an international team of ... is contributing to what appears to be the early ... , Since 1500, more than 320 terrestrial vertebrates have ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... of the body, the great majority of genes are silenced, ... up chromosomes. Estimates are that only about 10 percent of ... or "on," at any given time in a particular cell ... , Reliable gene silencing is vital to the health of ...
... have discovered a gene in fruit flies that helps ... The study, published in the April 4 issue of ... in mammals. , In teasing apart the molecular interactions ... gene they dubbed "Lazaro" that is expressed 15 times ...
... industry, including cruise lines, local governments and shore ... are taking proactive measures to ensure a sustainable ... according to a new report titled From Ship ... by Conservation International's (CI) Center for Environmental Leadership ...
Cached Biology News:New mechanism for essential genome-wide gene silencing identified 2New gene reduces retinal degeneration in fruit flies 2Report finds cruise industry is protecting the precious places it visits 2Report finds cruise industry is protecting the precious places it visits 3Report finds cruise industry is protecting the precious places it visits 4
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 At the ... has granted a 60-day extension for the public comment ... Special Rule for Model Aircraft established by Congress as ... 2012. The 60-day extension establishes the new deadline for ... States Department of Transportation/FAA notice published in the Federal ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... caused by mutations in the gene responsible for making ... and developing new therapies has been hampered by the ... fail to develop many of the symptoms seen in ... April issue of the Journal of Clinical Investigation have ...
... 6 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) today ... treat bronchiectasis has been accepted for evaluation by,China,s ... pharmaceutical companies are required to undertake a study ... application.,Approval of the clinical trial application is expected ...
... PALO ALTO, Calif., March 6 Jazz,Pharmaceuticals, Inc. ... the,public to a live webcast of the company,s ... 10:00 a.m. Eastern Time/7:00 a.m.,Pacific Time on Thursday, ... last,approximately two hours., Members of Jazz Pharmaceuticals, ...
Cached Biology Technology:Pharmaxis' First Steps into China 2
...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Biology Products: